These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
568 related articles for article (PubMed ID: 25795402)
1. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F; Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402 [TBL] [Abstract][Full Text] [Related]
2. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558 [TBL] [Abstract][Full Text] [Related]
3. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Balleyguier C; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bardet A; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Archambaud B; Duffaud F; Lancet Oncol; 2022 Aug; 23(8):1044-1054. PubMed ID: 35835135 [TBL] [Abstract][Full Text] [Related]
4. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308 [TBL] [Abstract][Full Text] [Related]
5. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Tap WD; Papai Z; Van Tine BA; Attia S; Ganjoo KN; Jones RL; Schuetze S; Reed D; Chawla SP; Riedel RF; Krarup-Hansen A; Toulmonde M; Ray-Coquard I; Hohenberger P; Grignani G; Cranmer LD; Okuno S; Agulnik M; Read W; Ryan CW; Alcindor T; Del Muro XFG; Budd GT; Tawbi H; Pearce T; Kroll S; Reinke DK; Schöffski P Lancet Oncol; 2017 Aug; 18(8):1089-1103. PubMed ID: 28651927 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065 [TBL] [Abstract][Full Text] [Related]
15. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT; Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752 [TBL] [Abstract][Full Text] [Related]
16. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406 [TBL] [Abstract][Full Text] [Related]
17. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804 [TBL] [Abstract][Full Text] [Related]